IgA Nephropathy Needs a Diagnostic Marker of Immunologic Activity to Select the Right Patients for Immunotherapies

In this issue of JASN , Xie et al. [1][1] report on a histopathologic marker of immunologic activity in IgA nephropathy (IgAN) that predicts treatment response to immunotherapy. IgAN is the most prevalent primary GN and progresses to ESKD in almost one-third of patients. As mesangial IgA and